Your session is about to expire
← Back to Search
Methylation-based Prognostic Assay for Barrett's Esophagus
N/A
Waitlist Available
Research Sponsored by Capsulomics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial will see how new test results help doctors make decisions about monitoring and treating Barrett's esophagus.
Who is the study for?
This trial is for board-certified gastroenterologists in the U.S. who have been practicing for over 2 years, speak English, see at least 50 Barrett's esophagus patients a year, and have internet access. They should not have used the methylation assay test before.Check my eligibility
What is being tested?
The study tests how doctors decide on surveillance and treatment for Barrett's esophagus when given educational materials about a new prognostic methylation-based assay developed by Capsulomics.See study design
What are the potential side effects?
Since this trial involves educational materials rather than medical treatments or drugs, there are no direct physical side effects to participants.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical performance change in physician behavior.
The impact of methylation assay on physician confidence in clinical care decision-making.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
The intervention group will receive standard-of-care clinical data for their virtual cases along with educational materials about the methylation assay. This group will then be provided with methylation assay data to be used in addition to clinical data.
Group II: Control GroupActive Control1 Intervention
The control group will receive standard-of-care clinical data for their virtual patient cases. No educational material on the methylation assay will be provided.
Find a Location
Who is running the clinical trial?
Capsulomics, Inc.Lead Sponsor
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Intervention Group
- Group 2: Control Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there an opportunity for patients to join this experiment?
"The clinicaltrials.gov website reports that this trial is not currently open for recruitment. Initially posted on January 26th 2021 and last edited April 26th 2023, no patients are being sought out at the moment; however, there exist 230 other trials with an active search for test subjects."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger